The international scandal of defective asparaginase: A blight on children with cancer

Abstract

AbstractAcute lymphoblastic leukemia is the commonest form of cancer in children and adolescents worldwide, and asparaginase is an essential component of successful chemotherapy for this disease associated with long‐term survival rates often exceeding 90% in high‐income countries. Demonstrably defective preparations of asparaginase, distributed from China and India, increase the burden of morbidity and mortality, reducing attainable survival rates. This adverse outcome is enabled by inadequate regulation and oversight, especially in resource‐poor settings in low‐ and middle‐income countries where the great majority of children and adolescents with cancer live. The pediatric oncology community must rise to the challenge.